The Immunotherapy Cola Wars

Article

It's been a big week for immunotherapy for lung cancer. Right on the heels of a press release that the PD-1 inhibitor Opdivo (nivolumab) significantly improved survival for patients with advanced non-squamous NSCLC, my friend Dr. Garon from UCLA presented results at the American Association for Cancer Research conference with another PD-1 inhibitor, Keytruda (pembrolizumab).